Sunquest Acquires GeneInsight
News Apr 05, 2016
The GeneInsight platform was developed by Partners HealthCare and has been in continuous clinical use since 2005 at the Laboratory for Molecular Medicine. In 2014, Sunquest made a strategic investment in GeneInsight and established an alliance with Partners to accelerate genomic-based medicine. Since that time, Sunquest and Partners have collaborated to provide seamless genetic testing workflow capabilities to geneticists and pathologists alike.
“We are at the beginning of the most exciting decade in healthcare, and precision medicine is one of our highest priorities for innovation,” said Matthew Hawkins, president of Sunquest. “GeneInsight is the most clinically-proven platform on the market and advances our ability to deliver a complete and integrated workflow for both inherited and somatic testing efforts. We will continue to invest in GeneInsight and introduce additional solutions that advance molecular and genomic-based diagnostics.”
Sunquest’s investment in GeneInsight supports its efforts to integrate genetics into routine diagnostic workflows and make findings available to clinicians globally in real-time. Sunquest, with more than 30 years of laboratory IT experience, will provide integration capabilities with other healthcare IT vendors including EHRs, LIMS and genetic content providers. The company will also continue to further develop VariantWire, a networking infrastructure and crowd-sourcing platform designed to enable high-throughput transfer of structured genetic data between and among laboratories and clinicians.
Under the terms of the agreement, GeneInsight will become a wholly-owned subsidiary of Sunquest and maintain its existing Boston-based office.
“GeneInsight’s goal is to provide clinicians and laboratories with the ability to constantly improve clinical genetic processes and enable deeper cross-organizational communication for the benefit of patients,” said Sandy Aronson, executive director of information technology, Partners HealthCare’s Personalized Medicine and a founder of GeneInsight. “Sunquest will bring the GeneInsight solution to far more institutions, furthering its integration into pathology workflows and, by doing so, enable it to help many more people.”
Scientists at Tokyo Tech, Ricoh co. and The National Institute of Advanced Industrial Science and Technology have developed an ultra-low-power atomic clock (ULPAC) for small satellites to enable future communication systems beyond 5G. The proposed device outperforms the current industry standards in various benchmarks, such as size, stability, and power consumption.
With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019